BRIEF-Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

Reuters
25 Mar
BRIEF-Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

March 25 (Reuters) - Palatin Technologies Inc PTN.A:

  • PALATIN'S ORAL MC4R AGONIST PL7737 RECEIVES FDA ORPHAN DRUG DESIGNATION FOR OBESITY DUE TO LEPTIN RECEPTOR DEFICIENCY

  • PALATIN TECHNOLOGIES INC - PLANS IND SUBMISSION FOR PL7737 IN 4Q25

  • PALATIN TECHNOLOGIES INC - EXPECTS CLINICAL DATA FOR PL7737 IN 1H26

Source text: ID:nPnch98dka

Further company coverage: PTN.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10